Skip to content

Dare Bioscience, Inc.: 10-Q filed 2025-11-13

What Dare Bioscience, Inc. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 35 published measures, 108 facts as tagged in accession 0001401914-25-000050.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001401914-25-000050 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Dare Bioscience, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3030,748,574USD
At 2024-12-3122,101,131USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3027,890,671USD
At 2024-12-3128,113,220USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-302,857,903USD
At 2025-06-30-12,733,260USD
At 2025-03-31-9,563,701USD
At 2024-12-31-6,012,089USD
At 2024-09-30-1,484,483USD
At 2024-06-302,671,506USD
At 2024-03-31-10,999,410USD
At 2023-12-31-5,047,640USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3023,075,261USD
At 2024-12-3115,698,174USD
At 2024-09-3011,232,609USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-3,562,766USD92
2025-01-01 to 2025-09-30-11,957,556USD273
2025-04-01 to 2025-06-30-4,016,483USD91
2025-01-01 to 2025-03-31-4,378,307USD90
2024-07-01 to 2024-09-30-4,702,501USD92
2024-01-01 to 2024-09-301,452,799USD274
2024-04-01 to 2024-06-3012,910,656USD91
2024-01-01 to 2024-03-31-6,755,356USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-11,330,134USD273
2024-01-01 to 2024-09-30167,637USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-09-30178,637USD273
2024-01-01 to 2024-09-3010,197USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,262USD92
2025-01-01 to 2025-09-306,517USD273
2024-07-01 to 2024-09-3041,691USD92
2024-01-01 to 2024-09-3073,431USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-3018,853,015USD273
2024-01-01 to 2024-09-30565,842USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-178,637USD273
2024-01-01 to 2024-09-30-10,197USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-187,247,186USD
At 2024-12-31-175,289,630USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3012,755,112shares92
2025-01-01 to 2025-09-3010,143,078shares273
2024-07-01 to 2024-09-308,534,433shares92
2024-01-01 to 2024-09-308,656,856shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3012,755,112shares92
2025-01-01 to 2025-09-3010,143,078shares273
2024-07-01 to 2024-09-308,534,433shares92
2024-01-01 to 2024-09-308,683,610shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.28USD/shares92
2025-01-01 to 2025-09-30-1.18USD/shares273
2024-07-01 to 2024-09-30-0.55USD/shares92
2024-01-01 to 2024-09-300.17USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.28USD/shares92
2025-01-01 to 2025-09-30-1.18USD/shares273
2024-07-01 to 2024-09-30-0.55USD/shares92
2024-01-01 to 2024-09-300.17USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-301,657,255USD
At 2024-12-311,335,732USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,139,402USD273
2024-01-01 to 2024-09-301,713,996USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-3,672,148USD92
2025-01-01 to 2025-09-30-12,081,066USD273
2024-07-01 to 2024-09-30-4,681,349USD92
2024-01-01 to 2024-09-30-18,063,288USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3025,004,180USD
At 2024-12-3118,447,863USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3021,216,394USD
At 2024-12-3121,613,067USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-301,844,862USD
At 2024-12-311,455,832USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,674,410USD92
2025-01-01 to 2025-09-3012,087,583USD273
2024-07-01 to 2024-09-304,723,040USD92
2024-01-01 to 2024-09-3018,136,719USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,175,168USD92
2025-01-01 to 2025-09-304,901,311USD273
2024-07-01 to 2024-09-302,681,772USD92
2024-01-01 to 2024-09-3010,969,066USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3013,929,502shares
At 2024-12-318,700,386shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3023,375,261USD
At 2024-12-3115,998,174USD
At 2024-09-3011,532,609USD
At 2023-12-3110,811,056USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-09-30-395,966USD
At 2024-12-31-428,809USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30824,693USD
At 2024-12-311,206,942USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30898,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-301,018,373USD
At 2024-12-311,110,594USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-302,324,931USD
At 2024-12-313,042,918USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-3,555,906USD92
2025-01-01 to 2025-09-30-11,924,713USD273
2024-07-01 to 2024-09-30-4,679,566USD92
2024-01-01 to 2024-09-301,451,070USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,499,242USD92
2025-01-01 to 2025-09-307,186,272USD273
2024-07-01 to 2024-09-302,041,268USD92
2024-01-01 to 2024-09-307,159,979USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,100,091USD273
2024-01-01 to 2024-09-3035,957USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-07-01 to 2025-09-30109,382USD92
2025-01-01 to 2025-09-30123,510USD273
2024-07-01 to 2024-09-30-21,152USD92
2024-01-01 to 2024-09-30-863,289USD274

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-07-01 to 2025-09-30164,900USD92
2025-01-01 to 2025-09-30493,900USD273
2024-07-01 to 2024-09-30160,200USD92
2024-01-01 to 2024-09-30478,700USD274

Inspect the source

Entity
Dare Bioscience, Inc. / CIK 0001401914
Captured
2026-09-20T08:00:44.110Z
SEC response SHA-256
1a9e5d436251c8650231f065c4c293fc1bb2b6e8877619128801af21ceea9ac3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001401914.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))